Share on StockTwits

Boston Scientific Corp. (NYSE:BSX) Director Ernest Mario sold 17,104 shares of the company’s stock in a transaction dated Thursday, February 6th. The shares were sold at an average price of $12.80, for a total value of $218,931.20. Following the completion of the sale, the director now directly owns 347,855 shares in the company, valued at approximately $4,452,544. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Several analysts have recently commented on the stock. Analysts at Jefferies Group raised their price target on shares of Boston Scientific Corp. from $12.00 to $13.00 in a research note to investors on Wednesday. Separately, analysts at Cowen and Company raised their price target on shares of Boston Scientific Corp. from $14.00 to $15.00 in a research note to investors on Friday, January 31st. Finally, analysts at Piper Jaffray upgraded shares of Boston Scientific Corp. from a “neutral” rating to an “overweight” rating in a research note to investors on Tuesday, January 21st. They now have a $18.00 price target on the stock, up previously from $12.00. Ten equities research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company. The company presently has a consensus rating of “Buy” and an average target price of $12.27.

Boston Scientific Corp. (NYSE:BSX) traded up 2.10% during mid-day trading on Friday, hitting $13.10. The stock had a trading volume of 15,209,542 shares. Boston Scientific Corp. has a 1-year low of $7.07 and a 1-year high of $14.08. The stock’s 50-day moving average is $12.84 and its 200-day moving average is $11.84. The company’s market cap is $17.491 billion.

Boston Scientific Corp. (NYSE:BSX) last issued its quarterly earnings data on Tuesday, February 4th. The company reported $0.21 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.13 by $0.08. The company had revenue of $1.84 billion for the quarter, compared to the consensus estimate of $1.83 billion. During the same quarter last year, the company posted $0.18 earnings per share. Boston Scientific Corp.’s revenue was up .9% compared to the same quarter last year. On average, analysts predict that Boston Scientific Corp. will post $0.51 earnings per share for the current fiscal year.

Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.